We next sought to understand the association between ERBB2 expression and response to chemotherapy in two cohorts of patients with HER2-negative breast cancer (i.e., a neoadjuvant taxane-anthracycline-based cohort, hereafter GSE2506615, and the neoadjuvant eribulin SOLTI-1007-NeoEribulin cohort14). Here, ERBB2 is linked to breast carcinoma.